Summary Leads to the cellular effects of the anti-arthritic gold complexes may come from the the determination of their metabolism by target cells 
of the activity of aurothiomalate in the treatment of polyarthritis in Hooded Wistar rats. Activity of aurothiomalate is only shown in animals which received thiocyanate. Hydrogen cyanide is a constituent of cigarette smoke and the aurocyanide formed by the interaction with gold complexes and inhaled hydrogen cyanide rapidly diffuses into red blood cells. Because of the metabolism of hydrogen cyanide to thiocyanate in the liver, there are higher plasma levels of thiocyanate in smokers than in non-smokers. Smokers may have a greater incidence of side effects than nonsmokers but there appears to be little difference in therapeutic response, possibly because there is sufficient thiocyanate in extracellular fluid, even in non-smokers, to support the conversion of gold complexes to aurocyanide. The relationship between the metabolism and effects of the orally active gold complex, auranofin are less clear. Auranofin itself is taken up by cells with the loss of the ligands bound to gold while its inhibitory activity against the oxidative burst of PMN decreases with increasing cell density. For example, the lucigenin-dependent chemiluminescence of 106 PMN/ml is 46 pement of control at 0.5 M auranofin but only 2.2 pement in 2.105 PMN/ml in the presence of the same concentration of auranofin. A potentially active gold complex is a plasma component which is taken up by red blood cells.
Gold complexes are one of the groups of drugs used in the long term treatment of rheumatoid arthritis. They are problematic drugs because of their potentially serious side effects and limited therapeutic efficacy. Curtailment of their use has been recommended recently [1] but, while the clinical use of the gold complexes is probably decreasing, they are still used in the treatment of rheumatoid arthritis, particularly when the disease is mild but progressive [2] . While the gold complexes are thus minor drugs, determination of their mechanism of action is still worthwhile.
More detailed knowledge of their cellular effects could lead to the development of complexes with improved therapeutic indices, to potential sites of action for new anti-rheumatic drugs and, possibly, even to the pathophysiological basis of rheumatoid arthritis. Leads on the biological interactions of complexes of other heavy metals may also be obtained in studies on the gold complexes. These phenomena should be considered in studies on the mechanism of action of the gold complexes. For the actions of the gold complexes to be understood at a molecular and cellular level, the spectrum of clinical effects must be explicable.
Aurocyanide hypothesis
One hypothesis which has been put forward is that the cellular effect of the gold complexes is mediated by aurocyanide [6, 7] . This hypothesis arose from studies on the distribution of gold in red blood cells. During treatment with aurothiomalate, gold is found in much higher concentrations in the red blood cells of smokers than in the same cells in non-smokers [8] [9] [10] . The reason is that hydrogen cyanide is inhaled by smokers and forms the very stable complex, aurocyanide (see below) which allows the gold to be taken up and bound to red blood cells [11] . Following 
The mixed complex may disproportionate to yield aurocyanide and the bis thiolate complex:
The bis thiolate complex may be formed from the liberated thiol and the parent polymeric thiol:
3. There are spectroscopic [7] and chromatographic data [19] demonstrating the formation of aurocyanide by activated PMN when thiocyanate and aurothiomalate are present. Like PMN, monocytes contain myeloperoxidase although the levels of the enzyme are lower than in PMN. Thus, monocytes may also convert thiocyanate to hydrogen cyanide and, consequently, lead to the production of aurocyanide. However, the synthesis of aurocyanide in suspensions of purified monocytes has not been examined as yet.
4. Aurocyanide is a common metabolite of aumthiomalate, aumthioglucose and auranofin in patients treated with these complexes [20] . The plasma concentrations are, however, very low, being about 0.1 to 1 pement of the concentrations which inhibit the functions of PMN and lymphocytes. However, the detection of aurocyanide indicates that this complex is available to cells and has some stability under in vivo conditions. 5. Aumcyanide inhibits the oxidative burst of PMN which are usually present in very high numbers in the synovial fluid of inflamed joints at all stages of rheumatoid arthritis. A feature of the effect of aurocyanide on PMN is that its effect is delayed (Figure 1 ). Initially, the oxidative burst is either not altered or slightly accelerated. Consistent with the delayed inhibition, the depolarisation of PMN, a phenomenon associated with the initiation of the burst, is not inhibited [21] .
Two (Table II) . Azide is an inhibitor of myelopemxidase and thus should decrease the conversion of thiocyanate to hydrogen cyanide and, consequently, the formation of aurocyanide and its effect on the oxidative burst of PMN. The effect of azide on thiocyanate/aurothiomalate is therefore consistent with the aumcyanide hypothesis. These results are again somewhat difficult to interpret since azide itself has a late inhibitory effect on lucigenindependent chemiluminescence and this experiment requires confirmation using an inhibitor with less influence on the baseline measurement of the oxidative burst. Furthermore, in order to conclude that A feature of the effect of aurocyanide on the proliferation of lymphocytes is that its effect increases when added late in the incubations. This is shown particularly at 0.5 IM aurocyanide. At this concentration, aurocyanide is without significant effect when added at the commencement of the incubations but there is considerable effect when added at 1 and 2 days after the commencement of the 3 day incubations (Table III) . This result indicates that aurocyanide has a direct effect on the lymphocytes arid not on the monocytes which are required for the activation of lymphocytes. Interestingly, tolerance to aurocyanide appears to develop. Thus, when aurocyanide is added twice; at the commencement of the incubations and at 2 days, the inhibitory effect of aurocyanide is less than that seen when added only once at 2 days (Table III) Apart from the slow clinical response to the gold complexes, the main feature of the clinical response to their use is the interpatient variation in both the therapeutic response and the development of side effects. The formation of aurocyanide may very well depend upon the numbers and level of activation of PMN and monocytes in joints and the access of aumcyanide to their target cells. As discussed above, PMN and monocytes may be responsible for the formation of aumcyanide, but may not be the ultimate target cell. Interpatient variation in the synthesis and delivery of aumcyanide to target cells could easily lead to the variable clinical response.
Clinical responses to the gold complexes indicate that their anti-rheumatic activity may decrease with continued treatment. Factors associated with the production of aumcyanide may lead to tolerance. According to the aurocyanide hypothesis, the formation of aurocyanide is dependent upon the activity of PMN or monocytes. If the activity of these cells subsides to a low level, the production of aurocyanide may be insufficient to produce a marked suppression of the inflammation of rheumatoid arthritis. However, the disease may continue at a low level although still sufficient to lead to joint damage. Our introductory work on the proliferation of lymphocytes indicates that resistance to aurocyanide may occur, also consistent with tolerance to gold complexes.
One of the most significant side effects of the gold complexes is the development of ulceration of mucous membranes of the mouth. Could this be related to the formation of aurocyanide? High levels of both peroxidase and a substrate, thiocyanate, are present in saliva. The subsequent production of hydrogen cyanide [25] This experiment indicated that, not only was the gold concentrated in the cells, but that the gold was separated from its ligands. The strong association between the gold and cells indicates that the cellular effects of auranofin may be dependent upon the numbers of cells in a cellular system as well as the concentration of the aumnofin. Thus, the amount of gold per cell should decrease with increasing cell densities, with the result that the cellular effects of auranofin should decrease with increasing cell density.
This prediction has now been observed experimentally (Table IV) . It is difficult to compare quantitatively the degree of inhibition at the two densities of PMN tested, because the fractional inhibition of the oxidative burst does not follow simple dose response relationships and the semilogarithmic plots of fractional inhibition versus concentration of auranofin are not parallel. The inhibitory effect of aumnofin is, however, generally greater at the lower concentration of auranofin (Table IV) . No such relationship between cell density and the activity of aumcyanide has been detected [6] . Overall, the cellular uptake and activity of auranofin has been studied in considerable detail but the relevance of this work to its clinical efficacy is, however, not clear since the work requires confirmation using metabolites which are present in plasma or at sites of rheumatoid disease.
